Julian Blagg

7.4k citations

94 papers · 3.5k indexed · 1 hit paper · h-index 30

Impact in

Computational Theory and Mathematics top 0.5%
- Computational Drug Discovery Methods
Organic Chemistry top 2%
- Asymmetric Synthesis and Catalysis
- Synthetic Organic Chemistry Methods
- Synthesis and biological activity

Papers in

Cell Biology 22
- Microtubule and mitosis dynamics 20
Organic Chemistry 27
- Asymmetric Synthesis and Catalysis 14
- Synthetic Organic Chemistry Methods 8

Co-authors: Paul Workman Nathan Brown Wolfgang Oppolzer David A. Price Travis T. Wager Nigel Greene Inés Rodríguez Stephen G. Davies
Journals: Bioorganic & Medicinal Chemistry Letters (11 papers)Journal of Medicinal Chemistry (7 papers)Journal of the Chemical Society Perkin Transactions 1 (5 papers)Synlett (4 papers)Cancer Research (4 papers)
Partner nations: United Kingdom United States Switzerland

In The Last Decade

Julian Blagg

90 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Physiochemical drug properties associated with in vivo toxicological outcomes 2008 · 675 citations

Peers

Countries citing papers authored by Julian Blagg

Since Specialization

Citations

This map shows the geographic impact of Julian Blagg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julian Blagg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julian Blagg more than expected).

Fields of papers citing papers by Julian Blagg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julian Blagg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julian Blagg. The network helps show where Julian Blagg may publish in the future.

Co-authors

The 25 scholars most cited alongside Julian Blagg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Julian Blagg Line = papers co-authored together Julian Blagg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Identification and characterization of the mediator kinase-dependent myometrial stem cell phosphoproteome PubMed ·jiwook Jeung, E. I. Bychkova, Robert S. Schenken, Long He, John Blenis, Julian Blagg, Shin-Fu Chen, Kuang‐Lei Tsai, Thomas G. Boyer	2021	4
2	Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736 Blood Advances ·Andrew S. Moore, Amir Faisal, Grace Wing-Yan Mak, Farideh Miraki‐Moud, Vassilios Bavetsias, Melanie Valenti, Gary Box, Albert Hallsworth, Alexis de Haven Brandon, Cristina P. R. Xavier, 憲一和泉, Andrew D.J. Pearson, Julian Blagg, Florence I. Raynaud, Rajesh Chopra, Suzanne A. Eccles, David Taussig, Spiros Linardopoulos	2020	20
3	Ligand discrimination between active and inactive activation loop conformations of Aurora-A kinase is unmodified by phosphorylation Chemical Science ·Sally Weldon, Research Ontario. Legislative Library, Julian Blagg, Liming Ying, Charlotte A. Dodson	2019	6
4	Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species European Journal of Pharmaceutical Sciences ·M. Anderson, Negin Sheybani, Angela Hayes, Manjuan Liu, Thao-Nguyen Nguyen, 어월, Butrus Atrash, Amir Faisal, Vassilios Bavetsias, Spiros Linardopoulos, Julian Blagg, Florence I. Raynaud	2019	4
5	Privileged Structures and Polypharmacology within and between Protein Families ACS Medicinal Chemistry Letters ·Joshua Meyers, N. Chessum, Intan Ayu Familia Nur Janah, N. Yi Mok, Birgit Wilding, Bhupati B. Mishra, Martin Rowlands, Michael Tucker, Lindsay E. Evans, Carl S. Rye, Anthony Steven Fritas Malca, Yann‐Vaï Le Bihan, Rosemary Burke, Michael D. Carter, Paul Workman, Julian Blagg, Nathan Brown, Rob L. M. van Montfort, Keith Jones, Matthew D. Cheeseman	2018	12
6	Dynamic Equilibrium of the Aurora A Kinase Activation Loop Revealed by Single‐Molecule Spectroscopy Angewandte Chemie International Edition ·Sally Weldon, В.А. Кондратюк, Peter Sheldrake, Julian Blagg, Liming Ying, Charlotte A. Dodson	2017	33
7	Dynamic Equilibrium of the Aurora A Kinase Activation Loop Revealed by Single‐Molecule Spectroscopy Angewandte Chemie ·Sally Weldon, В.А. Кондратюк, Peter Sheldrake, Julian Blagg, Liming Ying, Charlotte A. Dodson	2017	3
8	Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology Cancer Cell ·Julian Blagg, Paul Workman	2017	137
9	Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore Bioorganic & Medicinal Chemistry Letters ·Kai Schiemann, Aurélie Mallinger, Dirk Wienke, Christina Esdar, Oliver Poeschke, Michael Busch, Felix Rohdich, Suzanne A. Eccles, Richard Schneider, Florence I. Raynaud, Paul Czodrowski, Djordje Müsil, Dániel Schwarz, Klaus Urbahns, Julian Blagg	2016	30
10	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance Cancer Research ·Mark D. Gurden, Isaac M. Westwood, Amir Faisal, Sébastien Naud, Kwai-Ming J. Cheung, Craig McAndrew, Amy Wood, Long Yuan, Kathy Boxall, Grace Wing-Yan Mak, Paul Workman, Rosemary Burke, Swen Hoelder, Julian Blagg, Rob L. M. van Montfort, Spiros Linardopoulos	2015	24
11	Diverse Functionalization of Aurora-A Kinase at Specified Surface and Buried Sites by Native Chemical Modification PLoS ONE ·Halil Özer, 魏晓芳, Carla Fernandes, Richard Bayliss, Julian Blagg	2014	12
12	The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN -Amplified Neuroblastoma In Vivo Molecular Cancer Therapeutics ·Amir Faisal, S. S. Nedev, Vassilios Bavetsias, Chongbo Sun, Butrus Atrash, Б И Лобов, Yann Jamin, Simon P. Robinson, Paul Workman, Julian Blagg, Florence I. Raynaud, Suzanne A. Eccles, Louis Chesler, Spiros Linardopoulos	2011	67
13	Analysis of water patterns in protein kinase binding sites Proteins Structure Function and Bioinformatics ·Caterina Barillari, Anna L. Duncan, Isaac M. Westwood, Julian Blagg, Rob L. M. van Montfort	2011	20
14	A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription Cancer Research ·Kenneth Ewan, Bożena Pająk, Mark Stubbs, E A Davies, Olivier Barbeau, Camilo Quevedo, Hannah Botfield, Rodrigo Young, Ruth Ruddle, Joona Luukka, Alysia Battersby, Florence I. Raynaud, Nicholas D. Allen, Stephen W. Wilson, Branko Latinkic, Paul Workman, Edward McDonald, Julian Blagg, Wynne Aherne, Trevor Dale	2010	86
15	Evaluation of germline BMP4 mutation as a cause of colorectal cancer Human Mutation ·Steven Lubbe, Alan Pittman, M. Husseien, Philip Twiss, Bianca Olver, Marcin Tadeusz Kania, Mobshra Qureshi, Nathan Brown, Emma Nye, Gordon Stamp, Julian Blagg, Richard S. Houlston	2010	27
16	Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells Bioorganic & Medicinal Chemistry Letters ·Nathalie Bouloc, Jonathan M. Large, Magda Kosmopoulou, Chongbo Sun, Amir Faisal, Mizio Matteucci, Jóhannes Reynisson, Nathan J. Brown, Butrus Atrash, Julian Blagg, Edward McDonald, Spiros Linardopoulos, Richard Bayliss, Vassilios Bavetsias	2010	27
17	Design and synthesis of pyridazinone-based 5-HT2C agonists Bioorganic & Medicinal Chemistry Letters ·Charlotte Allerton, Mark D. Andrews, Julian Blagg, David Ellis, JOHN R. KRUEGER, Jasson Alejandro, Kevin K.‐C. Liu, Gordon McMurray, Michael J. Ralph, K A Somanna, Robyn L. Ward, Tarso do Amaral de Souza Cruz	2009	27
18	Physicochemical drug properties associated within vivotoxicological outcomes: a review Expert Opinion on Drug Metabolism & Toxicology ·David A. Price, Julian Blagg, Lyn H. Jones, Nigel Greene, Travis T. Wager	2009	107
19	Small, non-peptide C5a receptor antagonists: Part 2 Bioorganic & Medicinal Chemistry Letters ·Julian Blagg, Charles E. Mowbray, David C. Pryde, Gary Salmon, David Fairman, Esther F. Schmid, Kevin Beaumont	2008	8
20	The Metabolism and Toxicity of Furosemide in the Wistar Rat and CD-1 Mouse: a Chemical and Biochemical Definition of the Toxicophore Journal of Pharmacology and Experimental Therapeutics ·Dominic P. Williams, Daniel J. Antoine, Wengliang Liu, Russell G. Jones, Laura E. Randle, Anthony G. Payne, Martin Howard, Iain Gardner, Julian Blagg, B. Kevin Park	2007	50

About Julian Blagg

Julian Blagg is a scholar working on Cell Biology, Organic Chemistry, Pharmacology, Molecular Biology and Computational Theory and Mathematics, having authored 94 papers that have together received 3.5k indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (20 papers), Asymmetric Synthesis and Catalysis (14 papers), Epigenetics and DNA Methylation (12 papers), Protein Degradation and Inhibitors (12 papers), Cancer-related Molecular Pathways (11 papers), Computational Drug Discovery Methods (11 papers), Synthetic Organic Chemistry Methods (8 papers) and Pharmacogenetics and Drug Metabolism (6 papers). The work is most often cited by research in Computational Theory and Mathematics (714 citations), Organic Chemistry (1.2k citations), Pharmacology (258 citations), Molecular Biology (1.8k citations) and Cell Biology (403 citations). Julian Blagg has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Paul Workman, Nathan Brown, Wolfgang Oppolzer, David A. Price, Travis T. Wager, Nigel Greene, Inés Rodríguez, Stephen G. Davies, Eric Walther and Simon Bailey. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Journal of the Chemical Society Perkin Transactions 1, Synlett and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact